Authors: Sane, DC Damaraju, LV Topol, EJ Cabot, CF Mascelli, MA Harrington, RA Simoons, ML Califf, RM

Citation: Dc. Sane et al., Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy, J AM COL C, 36(1), 2000, pp. 75-83

Authors: Lincoff, AM Mark, DB Tcheng, JE Califf, RM Bala, MV Anderson, KM Davidson-Ray, L Knight, JD Cabot, CF Topol, EJ

Citation: Am. Lincoff et al., Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization - Results from the EPILOG randomized trial, CIRCULATION, 102(24), 2000, pp. 2923-2929

Authors: Lincoff, AM LeNarz, LA Despotis, GJ Smith, PK Booth, JE Raymond, RE Sapp, SK Cabot, CF Tcheng, JE Califf, RM Effron, MB Topol, EJ

Citation: Am. Lincoff et al., Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials, ANN THORAC, 70(2), 2000, pp. 516-526

Authors: Topol, EJ Mark, DB Lincoff, AM Cohen, E Burton, J Kleiman, N Talley, D Sapp, S Booth, J Cabot, CF Anderson, KM Califf, RM

Citation: Ej. Topol et al., Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial, LANCET, 354(9195), 1999, pp. 2019-2024

Authors: Lincoff, AM Califf, RM Moliterno, DJ Ellis, SG Ducas, J Kramer, JH Kleiman, NS Cohen, EA Booth, JE Sapp, SK Cabot, CF Topol, EJ

Citation: Am. Lincoff et al., Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors, N ENG J MED, 341(5), 1999, pp. 319-327

Authors: Lincoff, AM Tcheng, JE Califf, RM Kereiakes, DJ Kelly, TA Timmis, GC Kleiman, NS Booth, JE Balog, C Cabot, CF Anderson, KM Weisman, HF Topol, EJ

Citation: Am. Lincoff et al., Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab - One-year outcome in the EPILOG trial, CIRCULATION, 99(15), 1999, pp. 1951-1958